Welcome to our dedicated page for Brainsway news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway stock.
BrainsWay Ltd. reports developments in noninvasive neurostimulation treatments for mental health disorders. The company markets its proprietary Deep TMS platform, with FDA-cleared indications that include major depressive disorder, obsessive-compulsive disorder, and smoking addiction, and derives revenue from leases and sales of Deep TMS systems.
Recurring updates include financial results, operating guidance, system placements, reimbursement and payer coverage for TMS therapy, clinical data for Deep TMS protocols such as SWIFT, and additional regulatory clearances. Company news also covers strategic minority-stake and milestone-based investments in mental health providers and related neurostimulation technologies, along with investor conference participation and operational updates across its U.S. and Israel-based business.
BrainsWay (NASDAQ & TASE:BWAY) entered a strategic equity financing agreement with APS Innovations, parent of Chicago-area mental health provider Hopemark Health. BrainsWay will invest $1.5 million initially, with up to an additional $1.5 million via milestone-based investments for a minority preferred, annually compounding stake.
The security includes a redemption mechanism. The deal aligns with BrainsWay’s strategy to partner with growth-focused clinical platforms to expand access to Deep TMS and other advanced interventional psychiatry treatments across North America.
BrainsWay (NASDAQ:BWAY) reported strong Q1 2026 results, with revenue up 35% year-over-year to $15.5 million and net income more than doubling to $2.3 million. Adjusted EBITDA rose 117% to $2.8 million, operating income reached $2.0 million, and gross margin held at 75%.
Remaining performance obligations increased 25% to $75 million, and a record 117 Deep TMS systems shipped, lifting the installed base to about 1,820. Cash totaled $58.9 million. BrainsWay reiterated 2026 guidance for $66–$68 million revenue, 13%–14% operating margin, and $12–$14 million Adjusted EBITDA.
BrainsWay (NASDAQ: BWAY) will report first-quarter 2026 financial results and operational highlights before U.S. markets open on Wednesday, May 13, 2026. A live conference call and webcast are scheduled for 8:30 AM ET, with replay available for 30 days on the company investor website.
Dial-in, conference ID and webcast registration details are provided; attendees are asked to join at least 10 minutes early to register.
BrainsWay (NASDAQ: BWAY) highlighted expanding U.S. payer policies permitting psychiatric mental health nurse practitioners (PMHNPs) to order, supervise, and administer Transcranial Magnetic Stimulation, including Deep TMS™, where state scope-of-practice allows.
Optum Behavioral Health updated its policy in late 2025, covering ~34.8 million lives; several MACs, VA, and TRICARE West have adopted similar approaches. BrainsWay notes this could expand access amid psychiatrist shortages and cites FDA clearance for Deep TMS for multiple indications.
BrainsWay (NASDAQ: BWAY) will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026 at 8:45 AM ET.
The presentation offers an investor-facing update; investors and analysts should contact their Needham & Co. representative to request meetings.
BrainsWay (NASDAQ: BWAY) completed a $6 million milestone-based convertible loan to Neurolief after the FDA granted Premarket Approval for Neurolief's Proliv™Rx system for treatment-resistant major depressive disorder (MDD).
BrainsWay has invested $11 million to date and may provide further funding, including up to $5 million in a third tranche tied to revenue milestones; BrainsWay also holds a call option to acquire Neurolief equity under defined pricing formulas.
Neurolief reported commercial scaling, including inclusion on the Veterans Affairs Federal Supply Schedule with FSS pricing for Proliv™Rx and Relivion®MG.
BrainsWay (NASDAQ/TASE: BWAY) completed a $1.0 million milestone-based investment in Axis Integrated Mental Health after Axis achieved a predefined revenue milestone under an August 2025 strategic equity financing agreement.
The transaction follows BrainsWay's original $2.3 million equity investment and takes the form of a minority, annually compounding preferred security with a redemption mechanism. BrainsWay said the investment aligns with its strategy to partner with U.S. mental health providers and increase access to care; Axis operates several mental health clinics in Colorado.
BrainsWay (NASDAQ: BWAY) reported strong Q4 and full‑year 2025 results, with Q4 revenue $14.5M (+27% YoY) and full‑year revenue of $52.2M (+27% YoY). Q4 adjusted EBITDA rose 53% to $2.3M; full‑year adjusted EBITDA was ~$7.0M. Remaining performance obligations grew 43% to ~$70M. The company issued 2026 guidance of $66–68M revenue (27%–30% growth), operating income target of 13%–14%, and adjusted EBITDA of $12–14M. Key operational milestones include FDA label expansion for adolescent MDD, insurer coverage for accelerated SWIFT protocol, a multicenter AUD trial for Deep TMS 360™, and Neurolief ProlivRx approval.
BrainsWay (NASDAQ: BWAY) published two peer-reviewed manuscripts showing its FDA-cleared SWIFT™ accelerated Deep TMS reduced the acute depression treatment phase by ~70%, delivering an 87.8% response rate, 78.0% remission rate, and median remission in 21 days versus 28 for standard treatment.
Patient-reported quality of life rose ~32 percentage points and ~60% regained normal-range functioning, improving access and retention for non-drug depression therapy.
BrainsWay (NASDAQ: BWAY) will report its fourth quarter and full year 2025 financial results on Wednesday, March 11, 2026 before U.S. markets open. A conference call and webcast will be held at 8:30 AM ET to discuss results and operational highlights.
Dial-in numbers, a webcast link, and a Conference ID are provided; the live broadcast will be available for replay for 30 days on the company investor website.